{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-007944","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.339390+00:00","generated_at":"2026-05-22T23:39:59.238996+00:00","sec_items":["2.05","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Interpace Biosciences restructures after Medicare LCD ends PancraGEN coverage","bullets":["Medicare LCD L39365 ends PancraGEN reimbursement as of April 24, 2025; no specimens after May 2.","Workforce reduction announced; severance costs $0.5-0.6M in Q2 plus $0.2M in Q1 2025.","Restructuring to cut annual cost of revenue and OpEx by $12.5-14.5M, offsetting ~1/3 of revenue loss.","Plan substantially complete by end of Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-007944","json":"https://secwatch.observer/filing/0001641172-25-007944.json","markdown":"https://secwatch.observer/filing/0001641172-25-007944.md","text":"https://secwatch.observer/filing/0001641172-25-007944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000164117225007944/0001641172-25-007944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000164117225007944/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T23:39:59.238996+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}